{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-26-000017","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.329511+00:00","generated_at":"2026-05-16T01:14:21.489435+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Tarsus reports FY2025 XDEMVY sales of $451.4M (+150% YoY); net loss narrows to $66.4M; guides peak >$2B","bullets":["Q4 2025 net product sales $151.7M (Q4 2024: $66.4M); full-year $451.4M; ~400,000 bottles delivered in 2025.","Full-year net loss $66.4M ($1.59 loss per share) vs $115.6M ($3.07) in 2024; Q4 net loss $8.4M ($0.20) vs $23.1M ($0.60).","Management guided XDEMVY peak sales potential >$2B; gross margin held at 93%; cash $417.3M at year-end.","Initiated Phase 2 trial of TP-04 for ocular rosacea (topline 1H 2027); TP-05 Phase 2 for Lyme prevention expected Q2 2026.","David E.I. Pyott (former Allergan CEO) appointed to board; DTC campaign boosted patient awareness of Demodex blepharitis to ~25%."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-26-000017","json":"https://secwatch.observer/filing/0001819790-26-000017.json","markdown":"https://secwatch.observer/filing/0001819790-26-000017.md","text":"https://secwatch.observer/filing/0001819790-26-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000017/0001819790-26-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000017/tars-20260223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:14:21.489435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}